Alzheimer’s Drug Market is estimated to be US$ 8.86 billion by 2030 with a CAGR of 9.0% during the forecast period

Alzheimer's disease is characterized by nerve cell degeneration in numerous parts of the brain. It impairs cognitive abilities such as memory, language, reasoning, and conduct. Depression, memory loss, loss of inhibitions, and issues with thinking and reasoning are all classic Alzheimer's symptoms. Physical checks, blood tests, brain imaging, and mental status and neuropsychological testing are commonly used to diagnose it. Doctors give various drugs to ease symptoms based on the findings. Neurotransmitters, the substances involved in transporting information between nerve cells in the brain, are influenced by Alzheimer's medicines. Companies are enhancing their product offerings and launching new products in response to advancements in diagnostic technologies and ongoing research activities in the area, which, when combined with other business expansion initiatives such as mergers and acquisitions, strategic collaboration, and new investments into other companies, are expected to complement the growth of the Alzheimer's disease diagnostics and therapeutics market over the forecast period. For instance, in August 2019, Oxford Brain Diagnostics (an Oxford University spinoff) was founded to provide a new way for diagnosing Alzheimer's disease using MRI images. High failure rates in clinical studies linked to diagnosis and treatment, as well as obstacles in early Alzheimer's disease diagnostics, are likely to stymie the expansion of Alzheimer's disease diagnostics and medicines.

Region Analysis:

North America is anticipated to expand the Alzheimer’s drugs market owing to presence of top key players and high prevalence of Alzheimer’s disease. For instance, presently, 5.8 million Americans are living with Alzheimer’s disease which is likely to grow by 14 million till 2050, which is expected to drive the Alzheimer’s drug market in North America. Furthermore, Europe is projected to augment the market during forecast period due to increasing cases of Alzheimer’s disease coupled with improving diagnostic capabilities. In Asia-Pacific and Latin America are anticipated to fuel the market due to rising awareness and evolving healthcare infrastructure during the forecast period.

Key Highlights:

• Salk Institute began a phase 1 clinical trial of the novel Alzheimer's medication CMS121 in October 2021 to assess its safety in people.
• In November 2021, Brigham and Women’s Hospital in Boston, Unites States, came forward for starting clinical trial to test the safety and efficacy of new nasal vaccine for Alzheimer’s disease.

Key Market Insights from the report:

The Global Alzheimer’s Drug Market accounted for US$ 3.79 billion in 2020 and is estimated to be US$ 8.86 billion by 2030 and is anticipated to register a CAGR of 9.0%.   The Global Alzheimer’s Drug Market has been segmented on the basis of drugs, distribution channel and region.

• Based on Drugs, Global Alzheimer’s Drug Market is segmented into Donepezil, Memantine, Galantamine, Rivastigmine, Donanemab and Gantenerumab.
• Based on Distribution Channel, Global Alzheimer’s Drug Market is segmented into Hospital Pharmacies, Retail Pharmacies and E-Commerce. 
• By Region, the Global Alzheimer’s Drug Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Alzheimer’s Drug Market:

The key players operating the Global Alzheimer’s Drug Market includes  Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.